Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 11
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of MOB.ST is 13 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Data is available to registered users only
Buy
Sell